41st week of 2019 patent applcation highlights part 7 |
Patent application number | Title | Published |
20190307655 | PERSONAL CARE COMPOSITION - Disclosed is a personal care composition comprising boron nitride in combination with a non-silicone polyolefin particle in a cosmetically acceptable carrier to provide benefits of enhanced skin appearance. | 2019-10-10 |
20190307656 | FOAM CONTAINING UNIQUE OIL GLOBULES - The present invention provides a foamable composition for administration to the skin, body surface, body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum. The foamable oil in water emulsion composition includes: an oil globule system, selected from the group consisting of oil bodies; and sub-micron oil globules, about 0.1% to about 5% by weight of an agent, selected from the group consisting of a surface-active agent, having an HLB value between 9 and 16; and a polymeric agent, and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition, water and optional ingredients are added to complete the total mass to 100%. Upon release from an aerosol container, the foamable composition forms and expanded foam suitable for topical administration. | 2019-10-10 |
20190307657 | ORAL CARE COMPOSITION CONTAINING AT LEAST ONE BIOSURFACTANT AND FLUORIDE - The present invention relates to oral care compositions comprising at least one biosurfactant and fluoride. | 2019-10-10 |
20190307658 | HAIR LIGHTENING COMPOSITION COMPRISING AN OXIDIZING AGENT, A CARBONATE AND AT LEAST 5% BY WEIGHT OF POLYPHOSPHORUS DERIVATIVE - The present invention relates to a composition for lightening keratin materials, preferably keratin fibres, in particular human keratin fibres such as the hair, comprising (a) hydrogen peroxide; (b) one or more carbonates and/or one or more carbonate-generating systems, (c) one or more polyphosphorus derivatives, in a total content of greater than or equal to 0.5% by weight, relative to the total weight of the composition, the pH of the composition being less than or equal to 9.7, the compositions being free of persalts. The invention also relates to a lightening process using said composition, and also to a multi-compartment device which is suitable for using said lightening composition. | 2019-10-10 |
20190307659 | COSMETIC TENSIONING COMPOSITION - A cosmetic composition having a film-forming tensioning polymer system and at least one hydrophilic non-colloidal particulate agent comprising precipitated silica particles is disclosed. The film forming composition comprises a first non-crosslinking polyamide/polyacrylate copolymer comprising at least one amide monomer; (meth)acrylate monomers; monomers having at least one carboxylic functional group; and monomers having at least one amine functional group. The film forming composition also comprises a second non-crosslinking polyamide copolymer comprising at least one amide; at least one quaternary ammonium containing monomer; and monomers having at least one amine functional group. | 2019-10-10 |
20190307660 | POLISHED TALC MICROBEADS - Polished talc microbeads, i.e. polished talc particles with a largest average diameter of less than 500 μm and methods for the preparation thereof, which microbeads are especially suitable to be use as an alternative for plastic microbeads used in cosmetics and personal hygiene products. Body scrubs, tooth pastes and soaps comprising the present polished talc microbeads. The use of polished talc microbeads with a talc content of more than 70% (w/w) and a largest diameter of less than 500 μm as a substitute for plastic microbeads in cosmetics and personal hygiene products. | 2019-10-10 |
20190307661 | Antiperspirant Chalk Composition and Method - A composition/formula mixture reduces perspiration and enhances grip for an athlete. The composition consists of a chalk component and an aluminum or zirconium additive, preferably one that is chlorohydrate-based, said additive being 35% or less of the composition. The composition may be applied as a powder, a liquid, a roll on, a solid or a spray. A method for using the aforesaid composition to improve an athlete's gripping performance is also disclosed. | 2019-10-10 |
20190307662 | COMPOSITIONS AND METHODS FOR STABILIZATION OF RETINOIDS - The present invention relates to a composition and method for stabilisation of compounds including retinoids using the synergistic effects of beta-carotene and sodium polyaspartate. | 2019-10-10 |
20190307663 | Oxidative Hair Dying and Conditioning Composition and Method for Base Breaking Hair with an Oxidative Hair Dye - An oxidative hair dying and conditioning composition and method for base breaking hair with an oxidative hair dye composition provides a hair dying and conditioning composition that consists of a nonionic surfactant having a hydrophilic-lipophilic balance (HLB) of 12 or less, at least one liquid oil agent, at least one alcohol defined by a carbon chain of at least 14 carbon atoms, at least one anion surfactant, at least one amphoteric surfactant, and at least one solvent. Further, a base breaking method helps remove the hair border line by reducing the contrast between a hair's natural base color and highlights through application of a first agent consisting of an oxidative dye and alkaline agent, and a second agent consisting of an oxidative agent that are applied to the hair in two phases separated by a duration of about ten minutes, and rinsing/drying the hair between applications. | 2019-10-10 |
20190307664 | METHOD AND COSMETIC COMPOSITION FOR ENHANCED TRANSDERMAL DELIVERY OF ALKYL SUBSTITUTED RESORCINOL - Disclosed is a cosmetic composition comprising: (i) at least one pyridine compound of Formula I or II: where, in said Formula I and in said Formula II, X is S or O; R, R | 2019-10-10 |
20190307665 | PRODUCT COMPOSITION COMPRISING A DISCRETE PARTICLE AND AN AQUEOUS BASE COMPOSITION - Disclosed is a product composition comprising: a discrete particle of a mixture composition, wherein the mixture composition comprises a surfactant and a high melting point fatty compound; and an aqueous base composition comprising a surfactant, a high melting point fatty compound, and an aqueous carrier, and wherein the aqueous base composition is substantially free of detersive surfactant. The product composition of the present invention provides at least one the followings: more flexibility in the product composition rheology; improved stability in the product composition; and improved deposition of benefit agents when the base composition further comprises such benefit agents. | 2019-10-10 |
20190307666 | PEPTIDE COMPOSITION AND RESPECTIVE USES - The present invention provides a composition that comprises at least one peptide with a sequence length of 6-12 amino acids, where 2-5 of those amino acids are cysteines for the treatment of the hair, including animal and human hair, without the use of chemicals harmful to the hair fiber and consumer health and uses of said compositions in shampoo, lotion, serum, cream, conditioner, foam, elixir, oil, aerosol or mask. | 2019-10-10 |
20190307667 | AQUEOUS COSMETIC - An aqueous cosmetic comprising:
| 2019-10-10 |
20190307668 | COSMETIC COMPOSITION COMPRISING A CATIONIC COPOLYMER - The first aspect of the present invention relates to a cosmetic composition comprising: (i) a copolymer comprising: (A) from 0.1 mol-% to 99.9 mol-% of one or more cationic structural units (A); and (B) from 0.1 mol-% to 99.9 mol-% of one or more macromonomeric structural units (B); and (ii) a cosmetically acceptable component; wherein the one or more cationic structural units (A) are represented by the general formulae (I) and/or (II) and the one or more macromonomeric structural units (B) are represented by the general formula (III). Preferably the composition is a shampoo for cleansing keratin fibres, more preferably is a hair cleansing composition. The invention also relates to a method of using a cosmetic composition comprising applying the composition according to first aspect to keratinous material. The invention also relates to Use of a cosmetic composition for volumising keratinous fibres, wherein the cosmetic composition is according to the first aspect. The invention also relates to a process for formulating a cosmetic composition comprising providing a copolymer and a cosmetically acceptable component and mixing the copolymer and a cosmetically acceptable component together to form a cosmetic composition. | 2019-10-10 |
20190307669 | COSMETIC COMPOSITION COMPRISING A PARTICULAR COMBINATION OF SURFACTANTS, A SILICONE, A CATIONIC POLYMER, A FATTY ALCOHOL AND A CLAY - The present invention relates to a composition comprising one or more cationic surfactants, one or more amphoteric or zwitterionic surfactants, one or more silicones, one or more cationic polymers, one or more fatty alcohols and one or more clays. The invention also relates to a cosmetic process for washing keratin fibres using this composition. Finally, the invention relates to the use of such a composition for washing keratin fibres. | 2019-10-10 |
20190307670 | FAT AND/OR WAX ACTIVATED BY MEANS OF THE WATER-INSOLUBLE FRACTION OF CARICA PAPAYA SAP - The invention relates to a method for obtaining the water-insoluble fraction of | 2019-10-10 |
20190307671 | Natural Hydrocarbon/Ester Compositions with Improved Sensory Properties, Formulations and Related Methods - Described herein is an invention that includes a spreadable conditioning composition comprising a blend of a branched hydrocarbon and an ester having a kinematic viscosity of less than or equal to about 100 centistokes. The composition may be natural, for example, if each of the branched hydrocarbon and the ester are independently vegetable-derived. In addition, the composition may lack ingredients that are derived from a palm oil. In an embodiment, the composition is a blend of hydrogenated farnesene and an esters selected from glyceryl triheptanoate, dicapryl succinate, heptyl undecylenate, and mixtures thereof. The composition exhibits an average spreading velocity of about 4 to about 8. | 2019-10-10 |
20190307672 | Solid Wax Composition and Solid Oily Cosmetic - The present invention provides a composition that has an excellent hardness adjustment action, can be used as a solidifying agent for various cosmetics, and when added to cosmetics, can impart those cosmetics with excellent shape retention properties, an oil oozing suppression effect during use, a favorable texture and good storage stability, and also provides an oily solid cosmetic to which the composition has been added. Specifically, the invention provides a solid wax composition containing a component (A):candelilla wax, and a component (B): a monoester having a total of 40 to 48 carbon atoms, wherein the mass ratio between the component (A) and the component (B) in the solid wax composition satisfies component (A):component (B)=45:55 to 95:5, and the monoester is a monoester of a monovalent fatty acid and a monohydric alcohol. | 2019-10-10 |
20190307673 | TRADITIONAL CHINESE MEDICINE PLANT COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF - A traditional Chinese medicine plant composition, comprising in parts by weight: 20-60 parts of | 2019-10-10 |
20190307674 | COSMETIC METHODS AND PRODUCTS - This invention relates to method of improving the appearance of skin or hair. In particular, it relates to cosmetic products such as creams and serums comprising a subject's own platelet rich plasma (PRP). The invention also relates to kits that allow the user to apply the cosmetic products daily for several days. | 2019-10-10 |
20190307675 | Oral Delivery System and Method - A system and method for infusion of active ingredients into a delivery device is disclosed. The active ingredients can be loaded into a variety of oral delivery devices, including but not limited to toothpicks, tongue depressors, ice cream sticks and cocktail stirrers. In an embodiment, these delivery devices might be made from various types of wood, one non-limiting example being birchwood. These oral delivery devices can be used to deliver various of the following active ingredients along with inactive ingredients such as flavor, natural, and/or artificial sweeteners, as well as other items not explicitly shown in this list: nicotine, smoking cessation products, caffeine, tetra hydro cannabinol (hereinafter referred to as THC), cannabidiol (hereinafter referred to as CBD), and dietary supplements. | 2019-10-10 |
20190307676 | COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS OR LONG-ACTING B2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS - Compositions, methods and systems are provided for pulmonary delivery of long-acting muscarinic antagonists and long-acting β | 2019-10-10 |
20190307677 | AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS - Provided are compounds of Formula I: | 2019-10-10 |
20190307678 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS - Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures. | 2019-10-10 |
20190307679 | Probiotic Confection and Lipid Compositions - The present application relates to probiotic confection-based compositions comprising lactic acid-producing bacteria and oil-based compositions comprising the same. | 2019-10-10 |
20190307680 | METHOD OF TREATING EPILEPSY - Alprazolam formulated as an inhaled condensation aerosol and method for treating epilepsy and/or seizures. | 2019-10-10 |
20190307681 | PHARMACEUTICAL COMPOSITIONS OF MELOXICAM - The present invention relates to storage stable emulsion formulations of meloxicam or its pharmaceutically acceptable salts, solvates and hydrates thereof suitable for parenteral administration. | 2019-10-10 |
20190307682 | POLYMERIC EMULSION DELIVERY SYSTEMS - Provided herein are compositions comprising an oil-in-water emulsion, wherein the emulsion comprises a liquid oil component; a cross-linked homopolymer based on acrylic acid and/or a cross-linked copolymer of acrylic acid and acrylic acid esters; and water. In some embodiments, the composition is a vehicle for the delivery of an active agent. | 2019-10-10 |
20190307683 | Ziyuglycoside II Polymer Micelle and Preparative Methods Thereof - The present invention discloses a ziyuglycoside II polymer micelle, and it is prepared by following raw/auxiliary materials at predetermined weight ratio: 20 parts of ziyuglycoside II and 100-5000 parts of mPEG-PLA-Phe(Boc). Quality evaluation test indicates that only using mPEG-PLA-Phe(Boc) according to the present invention as carrier materials, the quality of ziyuglycoside II polymer micelle prepared is the best, but using other additional materials can lead to the lowered preparation quality. In the pharmacodynamic experiment, compared with the model group, the ziyuglycoside II micelle of the present invention can significantly increase the amounts of WBC, RBC, PLT, NEUT, and HGB in peripheral blood, and the efficacy is obviously better than the original drug ziyuglycoside II, indicating the ziyuglycoside II polymer micelle of the present invention has a better treatment and/or prevention effects on bone marrow suppression, and can improve the bioavailability of insoluble drug ziyuglycoside II. | 2019-10-10 |
20190307684 | BLOCK COPOLYMERS AND SELF-ASSEMBLING NANOPARTICLES FORMED THEREFROM - The subject matter of this invention relates to block copolymers (BCPs) and, more particularly, to block copolymers capable of self-assembly into nanoparticles for the delivery of hydrophobic cargos. The BCPs include a hydrophobic block that contains a thioether functional group that is susceptible to oxidation, transforming the solubility of the block from hydrophobic to hydrophilic, thereby releasing the hydrophobic cargo of the nanoparticle. | 2019-10-10 |
20190307685 | NONSTEROIDAL IMMUNOMODULATING KIT AND COMPOSITION AND USES THEREOF - A composition and therapeutic kit including an aerosol packaging assembly including a container accommodating a pressurized product and an outlet capable of releasing a foamable composition, including a nonsteroidal immunomodulating agent as a foam. The pressurized product includes a foamable composition including:
| 2019-10-10 |
20190307686 | CULTIVATION OF PLACENTA TO ISOLATE EXOSOMES - Several approaches to produce, isolate, and characterize exosomes recovered from a cultivated placenta or a portion thereof are provided. The alternatives described herein facilitate the production, isolation, and characterization of exosomes, which can be used as biotechnological tools and therapeutics. Also provided herein are populations of exosomes derived from placenta organ culture or culture of portions of the placenta. Also provided are compositions comprising the populations of exosomes and methods of their use for the treatment of subjects. | 2019-10-10 |
20190307687 | MULTI-COMPONENT NANOCHAINS - A multi-component nanochain for use in diagnostic and therapeutic applications includes at least three nanoparticles linked together to form the nanochain. At least one nanoparticle of the nanochain has an asymmetric surface chemistry defined by asymmetrically disposed first linkers and second linkers. The nanoparticles are linked to form the nanochain by linking first linkers and/or second linkers disposed on separate nanoparticles. | 2019-10-10 |
20190307688 | NOVEL STEM CELL CARRIER AND METHOD FOR PREPARING THE SAME - The present disclosure relates to a novel stem cell carrier and a method for producing the same and provides a method for producing a stem cell carrier including a step of contacting stem cells with a coacervate formed by mixing an anionic polymer with a mussel adhesive protein or a mutant thereof. The present disclosure relates to a novel stem cell therapeutic agent platform of delivering cells in a encapsulated state by forming an adhesive cell carrier using crosslinked coacervate. The cell carrier of the present disclosure can maintain the ability to differentiate stem cells as well as biocompatibility and can survive without losing cell adhesion even under oxygen-deficient conditions. In addition, the cell carrier of the present disclosure has an excellent regenerative effect by applying such to biological tissues in which vascular regeneration is not easy, by inducing a metabolic reaction triggered by the hypoxic environment, in particular, neovascularization. | 2019-10-10 |
20190307689 | LIPID NANOPARTICLES FOR TRANSFECTION AND RELATED METHODS - Transfection reagent composition, lipid nanoparticles prepared from the transfection reagent composition, kits that include the transfection reagent composition, and methods for making and using lipid nanoparticles prepared from the transfection reagent composition. Lipids when dispersed in aqueous media readily form liposomes, such as unilamellar vesicles and multilamellar vesicles. Liposomes have been used successfully to encapsulate and deliver a wide range of chemicals including nucleic acids, proteins and, small molecule drugs, to cells. | 2019-10-10 |
20190307690 | Liposomal Delivery Systems for Oxaliplatin and in Dual Drug Delivery in Combination with Chemo-sensitizing and Chemo-therapeutic agents - A liposomal delivery composition to be administered through intravenous injection is provided for the treatment of cancer. The delivery composition has a liposome composition with therein encapsulated a first cancer drug (e.g. oxaliplatin) and a second cancer drug (e.g. ascorbic acid or satraplatin). The liposomal delivery composition has negative surface potentials resulting in an encapsulation efficiency for e.g. of oxaliplatin of about 20-25%. The liposomal delivery composition has a particle size of less than 200 nm. The liposomal delivery offers protection of the drug cargo, which reduces their non-intentional and non-pharmacological interactions thus reducing side effects and increases efficacy. Increased efficacy reduces the amount of drug given to a patient, which would reduce healthcare cost. The combinatory approach of two different drug cargos within the same liposome delivery composition allows for the synergistic action of these drugs. | 2019-10-10 |
20190307691 | HYDROGELS WITH LIPOSOMES FOR CONTROLLED RELEASE OF DRUGS - Compositions and methods are provided to control the release of small molecule and macromolecule drugs through hydrogels with dispersed stable liposomes. The mixture is formed into liposomes that are dispersed within bioabsorbable hydrogels, to release the therapeutic agents in a controlled fashion. Methods of using different compositions disclosed herein in respective therapeutic systems are also provided. | 2019-10-10 |
20190307692 | NANOLIPOPROTEIN PARTICLES AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR IMPROVED DRUG LOADING - Nanolipoprotein particles comprising at least a scaffold protein component and a membrane lipid component and related compositions, methods and systems are described, in which the membrane lipid component comprises at least one or more membrane forming lipids and one or more lysoplipids. | 2019-10-10 |
20190307693 | LIPOSOMAL STATIN FORMULATION - A method of preparing liposomal statins includes preparing a lipid solution including phosphatidylcholine, cholesterol, vitamin-E and an organic solvent and removing the solvent, forming a lipid cake. The lipid cake may then be hydrated with a first aqueous media. The hydrated cake may be mixed in a mixer and subjected to one or more freeze/thaw cycles and then extruded to form liposomes. A cryo-protective agent may be added to the liposomes and the liposomes may be lyophilized to provide a powder. A statin is added to the organic lipid solution or to the first aqueous media used for hydrating the lipid cake. | 2019-10-10 |
20190307694 | NEUROKININ-1 RECEPTOR ANTAGONIST COMPOSITION FOR TREATMENT OF DISEASES AND CONDITIONS OF THE RESPIRATORY TRACT - The present invention relates to a composition comprising a neurokinin-1 receptor antagonist and at least one excipient selected from an oil, a fatty acid or a polyol, as well as to an administration form for administering a formulation, wherein said administration form is selected from: inhalant, nebulization, vapor, smoke or aerosol and comprises said composition. In addition, the invention relates to said composition for use as medicament, said administration form for use as medicament, preferably said composition for use as medicament in the treatment of at least one disease of the respiratory tract, or said administration form for use as medicament in the treatment of at least one disease of the respiratory tract. Moreover, the invention also provides methods for producing said composition and said administration form, as well as a kit of parts comprising said composition and an administration device. | 2019-10-10 |
20190307695 | HEMP POWDER - A hemp powder is provided having at least 95% CBD along with some other percentage of extract plant material and other minor cannabinoids. In some examples, the hemp powder does not include additives, such as drying agents, anti-caking agents, or flow agents. | 2019-10-10 |
20190307696 | TABLETS COMPRISING MIRABEGRON AND SOLIFENACIN - The present invention relates to a pharmaceutical multi layer tablet comprising a controlled release part with mirabegron and an immediate release part wherein the immediate release formulation comprises: solifenacin succinate and a water insoluble diluent in an amount of 50 to 99% w/w relative to the total weight of the immediate release part of the tablet. The invention further relates to the use of said composition as a medicament, particularly in the treatment of urinary incontinence. | 2019-10-10 |
20190307697 | DELIVERY DEVICES AND METHODS FOR MAKING THE SAME - In an example of a method for making a pulsatile delivery device, one type of charges are generated on a polymeric layer, and charges opposite the one type of charges are generated on a delivery layer including a film forming material and a predetermined substance dispersed throughout the film forming material. The charged polymeric and delivery layers are placed into contact to form a bi-layer structure. A stack with at least two bi-layer structures is formed so that the polymeric layers and the delivery layers are alternating throughout the stack. The stack is sealed so that one of the polymeric layers remains exposed. | 2019-10-10 |
20190307698 | DIRECTLY COMPRESSIBLE MATRIX FOR THE PRODUCTION OF TABLETS HAVING EXTENDED RELEASE OF ACTIVE PHARMACEUTICAL INGREDIENT - The present invention relates to tablets having extremely long release of active pharmaceutical ingredient, to the particular composition thereof and to the production thereof. | 2019-10-10 |
20190307699 | DUAL RELEASE DOSAGE FORM CAPSULE AND METHODS, DEVICES AND SYSTEMS FOR MAKING SAME - Capsule forming machines that form a dual dosage capsule have superimposed upper and lower plates that are each rotatable about an axis of rotation. Each of the upper and lower plates define a plurality of voids for receiving a shell body or a capsule member of a capsule that are positioned to define a plurality of stations. A first distribution device is operatively positioned at one of the plurality of stations of each of the upper and lower plates and an actuator is operatively connected to either of the upper or lower plates. The actuator lifts and lowers the upper plate or the lower plate relative to the other plate and/or pivots the upper plate or the lower plate relative to the other plate transverse to the rotational axis to move a capsule assembly station thereof toward to the other plate and then away from the other plate at predetermined times. | 2019-10-10 |
20190307700 | RESVERATROL SOLUBILISATION PRODUCT FOR PHARMACEUTICAL PURPOSES - A solubilisation product consists of resveratrol, polysorbate 80 and polysorbate 20, at least one medium-chain triglyceride, and tocopherol. The solubilisation product is for use as a pharmaceutical product. The solubilisation product can be used as a pharmaceutical product in the treatment of Alzheimer's disease, Friedreich's ataxia, lysosomal diseases, in particular Tay-Sachs disease, cancer, diabetes, atherosclerosis, heart diseases, arthritis or autoimmune diseases. | 2019-10-10 |
20190307701 | Method Of Making An L-Menthol Dosage Form - A method of making an L-menthol dosage form includes forming a wet granulation including an L-menthol source and at least one pharmaceutical excipient. The wet granulation is extruded into an extrudate and the extrudate is cut into individual core pieces. The individual core pieces are spheronized into individual spheronized cores and the individual spheronized cores are dried to form dried individual spheronized cores. The dried individual spheronized cores are spray coated with a liquid proteinaceous material that forms a film of a proteinaceous material over the dried individual spheronized cores. The film of proteinaceous material is dried over the dried individual spheronized cores to form individual subcoated cores. An enteric coating is applied and dried over the individual subcoated cores to form a plurality of individual enteric coated cores. | 2019-10-10 |
20190307702 | MULTIPARTICULATES OF SPRAY-COATED DRUG AND POLYMER ON A MELTABLE CORE - A pharmaceutical composition comprises multiparticulates comprising a melt-congeal core and a solid amorphous dispersion layer of a poorly water soluble drug and polymer. The multiparticulates are suitable for improving bioavailability of poorly water soluble drugs. The melt-congeal cores facilitate application of the solid amorphous dispersion layer, and allow incorporation of additional optional components to the core so as to adjust the release of drug from the multiparticulate. | 2019-10-10 |
20190307703 | MULTI-FUNCTIONAL NANOPARTICLES FOR VACCINATION - The present invention generally relates to a dynamic nanoparticle used for vaccination. Specifically, the claimed product comprises of an adaptive nanoparticle wherein both the outer surface and the inner core are customizable for targeted application. | 2019-10-10 |
20190307704 | METHOD FOR ENHANCED DELIVERY OF GENE BASED THERAPY AND VACCINATION USING ELECTROPORATION - Embodiments of the present invention are generally related to a method of enhancing the transfection efficiency and immunological/pharmacological/therapeutic responses of concurrent gene-based vaccinations or therapies delivered by a wide range of non-viral particles, viral vectors or viral-biomaterials hybrid particles. In particular, embodiments of the present invention are directed to a method of electroporation which enhances the transfection efficiency of RNA replicon loaded lipid-based nanoparticles in-vivo as well as greatly improves immunogen-specific immune responses of such RNA-based vaccinations. This invention also applies to other gene-based vaccination and therapy using non-viral particles, viral based vectors or viral-biomaterials hybrid particles, in conjunction with the said electroporation regimen. | 2019-10-10 |
20190307705 | DEOXYRIBONUCLEIC ACID NANOPARTICLES FOR DELIVERING PROTEINS AND PROTEIN-CONTAINING COMPOUNDS AND METHODS OF MANUFACTURING DEOXYRIBONUCLEIC ACID NANOPARTICLES - Non-viral delivery platforms are provided for facilitating transport of molecules across cell membranes. In some forms, DNA nanoshells capable of transporting cargo molecules are formed, and may be formed in order to surround a variety of materials for a variety of purposes. | 2019-10-10 |
20190307706 | POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)B- UTANAMIDE - Disclosed herein are polymorphic and amorphous forms of anhydrate, hydrate, and solvates of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide and methods of using such compositions for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. Further disclosed are methods of making such polymorphic and amorphous forms. | 2019-10-10 |
20190307707 | METHODS OF ADMINISTERING AMANTADINE - Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration. | 2019-10-10 |
20190307708 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS - Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine. | 2019-10-10 |
20190307709 | MATERIALS AND METHODS FOR CONTROLLING INFECTIONS - The subject invention provides materials methods for reducing infections in subjects. The materials methods utilize chlorhexidine, which has been found to be surprisingly non-toxic. The lack of toxicity facilitates the use of chlorhexidine in contexts that were not previously thought to be possible. | 2019-10-10 |
20190307710 | NITRIC OXIDE RELEASING PLGA MICROSPHERES FOR BIOMEDICAL APPLICATIONS - A polymeric composition includes poly(lactide-co-glycolide) (PLGA) microspheres; and at least one of a discrete RSNO adduct or a polymeric RSNO encapsulated within the microspheres, with the at least one of the discrete RSNO adduct or the polymeric RSNO adduct capable of releasing nitric oxide (NO). The polymeric composition exhibits stability under dry conditions at 37° C. and prolonged and controllable NO release rates, when exposed to light capable of photolyzing an RSNO bond, or when exposed to moisture, for a predetermined amount of time from the at least one of the discrete RSNO adduct or the polymeric RSNO adduct. | 2019-10-10 |
20190307711 | Production Process For Nsaid-Containing Lozenges, Their Compositions, Their Medicinal Use - A process for producing a pharmaceutical lozenge formulation comprising the steps of: (a) providing a liquid composition comprising a salt of a non-steroidal anti-inflammatory drug (NSAID salt) and a solvent system, (b) providing a molten lozenge-forming composition, (c) mixing the liquid composition with the molten lozenge-forming composition, and, (d) forming the resulting mixture into lozenges each containing a therapeutically effective amount of said NSAID salt/NSAID mixture. The present application discloses the corresponding NSAID-containing lozenge compositions and their use for the manufacture of a medicament for treating sore throat. | 2019-10-10 |
20190307712 | CALCIUM LACTATE COMPOSITIONS AND METHODS OF USE - The invention relates to pharmaceutical compositions comprising calcium lactate as an active agent and a polysaccharide, polymer, lipid, or a combination thereof. The pharmaceutical compositions are useful treating cancer. The invention also relates to foods and nutrient compositions comprising calcium lactate. | 2019-10-10 |
20190307713 | COMBINATIONS OF DICLOFENAC AND H2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN AND INFLAMMATION - A single unit pharmaceutical dosage form comprising: diclofenac or a pharmaceutically acceptable salt thereof; and an H2 receptor antagonist, preferably famotidine or a pharmaceutically acceptable salt thereof, wherein diclofenac has a Tmax of between about and 50 minutes after administering said formulation to a patient. | 2019-10-10 |
20190307714 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS - In one aspect, methods of treating non-alcoholic steatohepatitis (NASH) or preventing or delaying the progression of non-alcoholic fatty liver disease (NAFLD) to NASH are provided. In some embodiments, the method comprises administering a therapeutically effective amount of ubenimex. | 2019-10-10 |
20190307715 | PREVENTION AND/OR TREATMENT OF NEURODEGENERATIVE DISEASE - A method for the prevention and/or treatment of mild cognitive impanment in a human subject; the method comprising the step of administering an effective amount of a composition comprising each of the following: lutein, zeaxanthin, meso-zeaxanthin, vitamin E, and at least one omega-3 fatty acid. | 2019-10-10 |
20190307716 | TOPICAL PHARMACEUTICAL COMPOSITIONS FOR TREATING SKIN CONDITIONS - In one aspect, topical pharmaceutical compositions for treating a skin condition or disorder are provided. In some embodiments, the topical pharmaceutical composition is formulated as a lotion and comprises a therapeutically effective amount of an active agent; a viscosity increasing agent; a polymeric emulsifier; and an oil component. In some embodiments, the topical pharmaceutical composition comprises tretinoin. | 2019-10-10 |
20190307717 | TOPICAL PHARMACEUTICAL COMPOSITIONS FOR TREATING SKIN CONDITIONS - Topical pharmaceutical compositions for treating a skin condition or disorder are provided. The topical pharmaceutical compositions can be formulated as lotions containing a therapeutically effective amount of an active agent, such as tretinoin, a viscosity increasing agent, and advantageously small amounts of both a polymeric emulsifier and an oil component. The topical compositions of the present invention are tolerated exceptionally well by subjects to whom the compositions are administered. | 2019-10-10 |
20190307718 | METHODS FOR TREATING CARDIOVASCULAR DISEASES - The present invention is directed to a method for treating cardiovascular diseases such as acute myocardial infarction, atherosclerosis, heart failure, stroke, thrombosis, carditis (including acute myocarditis, acute pericarditis and complicated pericarditis), cardiac allograft rejection, cardiomyopathy, and peripheral vascular diseases. The method comprises administering to a subject in need thereof dapansutrile, in an effective amount. A preferred route of administration is oral administration. | 2019-10-10 |
20190307719 | CANNABIS COMPOSITION - The invention relates to a method for treating a skin disorder. In particular, the invention provides a method for treating a skin disorder, comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition comprising a | 2019-10-10 |
20190307720 | Pharmaceutical Compositions Containing Cannabis, Uses Thereof and Methods for Alleviating Stress and/or Anxiety - A pharmaceutical composition containing | 2019-10-10 |
20190307721 | MAST CELL STABILIZERS TREATMENT FOR SYSTEMIC DISORDERS - Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided. | 2019-10-10 |
20190307722 | ANTIVIRAL COMPOSITIONS FOR THE TREATMENT OF INFECTIONS LINKED TO CORONAVIRUSES - The present invention relates to a pharmaceutical or veterinary composition for its use in preventing and/or treating a MERS-CoV (Middle-East Respiratory Syndrome) coronavirus infection, characterised in that it comprises, in a suitable pharmaceutical vehicle, at least one compound chosen from apigenin and berberine. | 2019-10-10 |
20190307723 | COMPOSITIONS AND METHODS FOR INTRAVENOUS ADMINISTRATION OF 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHANONE - The invention provides compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone (ABDNAZ), including formulations containing autologous whole blood and ABDNAZ that can be rapidly administered to a patient by intravenous infusion without any significant pain at the site of infusion. | 2019-10-10 |
20190307724 | Materials and Methods for Improving Gastrointestinal Function - The subject invention provides therapeutic compositions, and uses thereof for the treatment or amelioration of injury to small intestine mucosa. In preferred embodiments, the composition comprises one or more nutrients and/or electrolytes that acquire or retain considerable absorptive capacity. | 2019-10-10 |
20190307725 | PHOTODYNAMIC THERAPEUTIC COMPOUNDS AND PHOTODYNAMIC METHODS OF TREATMENT - The invention provides photodynamic therapeutic compounds and photodynamic methods of treatment. The photodynamic therapeutic compounds may be activated by long wavelength light. The photo-activation by long wavelength light may allow improved tissue penetration. The compounds are selected from the group consisting of compounds of formula (i), or a pharmaceutically acceptable salt thereof: formula (i) wherein PDC is a photodynamic core and wherein R1; R2; R3; and R4 are H, phenyl, pyridine-4-yl, methylpyridinium, N-methylpyridinium-3-yl; 2-phenyl-N-methylpyridinium-4-yl, 3-phenyl-N-methylpyridinium-4-yl, 4-phenyl-N-methylpyridinium-4-yl, 2-phenyl-N-methylpyridinium-3-yl, 3-phenyl-N-methylpyridinium-3-yl or 4-phenyl-N-methylpyridinium-3-yl; and wherein any one or more of R1, R2, R3 and R4 may be optionally substituted. | 2019-10-10 |
20190307726 | PHARMACEUTICAL FORMULATIONS - Disclosed herein is glutathione in conjunction with an isoselenazol or isothiazol derivative, e.g., ebselen or ebsulfur derivative, to treat diabetes, lupus, or other chronic inflammatory disease. The glutathione is preferably provided in a rapid release oral formulation that presents the glutathione for absorption in the first part of the ileum. The isoselenazol or isothiazol derivative is preferably provided in a delayed release formulation to avoid overlapping high enteric concentration. These may be provided within the same unit dosage form. | 2019-10-10 |
20190307727 | METHODS AND COMPOSITIONS FOR TREATING HYPERHIDROSIS - Aspects of the disclosure include methods for treating hyperhidrosis in a subject with a composition including a muscarinic antagonist and a muscarinic agonist. In practicing methods according to certain embodiments, a therapeutically effective amount of a composition including a muscarinic antagonist or a pharmaceutically acceptable salt thereof and a muscarinic agonist or a pharmaceutically acceptable salt thereof is administered to a subject and is sufficient to reduce hyperhidrosis in the subject and to reduce a dry mouth side effect of the muscarinic antagonist. Compositions for practicing the subject methods are also described as well as dose units containing one or more of the subject compositions. | 2019-10-10 |
20190307728 | METHODS OF TREATMENT WITH A 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONE - The present invention provides a method of treating a mutant IDH cancer in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound (I): | 2019-10-10 |
20190307729 | ANTIMICROBIAL COMPOUNDS AND METHODS FOR USE THEREOF - Compounds, pharmaceutical compositions, and methods for treatment of microbial infections are provided. The compounds can potentiate the therapeutic effects of one or more antimicrobial agents when co-administered. The compounds have antivirulence properties. Pharmaceutical compositions including the compounds and a pharmaceutically acceptable carrier are provided. The pharmaceutical composition can further include at least one antibiotic, such as, Gentamicin, amikacin, kanamycin, neomycin, spectinomycin, neamine or any combination thereof. The compounds and compositions can be used to treat or prevent microbial infections. | 2019-10-10 |
20190307730 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA - This invention is directed to methods for treating and preventing influenza infection by inhibiting influenza virus HA maturation processes employing compounds of formula I. It is also directed to combinations for treating and preventing influenza infection comprising compounds of formula I and other agents. | 2019-10-10 |
20190307731 | ARYL HYDROCARBON RECEPTOR MODULATOR - Disclosed is an aryl hydrocarbon receptor modulator of formula (I), and a pharmaceutically acceptable salt thereof, wherein | 2019-10-10 |
20190307732 | METHODS OF TREATING MITOCHONDRIAL AND METABOLIC DISORDERS - The present invention relates to methods and compositions for the treatment of diseases, such as mitochondrial-associated disorders, for example Leigh, MELAS, and NARP syndrome, and metabolic disorders, comprising administering an allosteric mTOR inhibitor, such as a composition comprising nanoparticles comprising an allosteric mTOR inhibitor and an albumin. Also provided are medicine and kits useful for the methods described herein. | 2019-10-10 |
20190307733 | METHODS AND COMPOSITIONS FOR TREATMENT OF EPILEPTIC DISORDERS - Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof. | 2019-10-10 |
20190307734 | FORMULATIONS OF ROLAPITANT - This document relates to compositions comprising a non-covalently bound complex comprising rolapitant and human serum albumin, wherein the rolapitant and the human serum albumin in the composition have a ratio by weight from about 1:20 to about 1:2000. This document also relates to compositions comprising rolapitant and human serum albumin, wherein the rolapitant and the human serum albumin in the composition have a ratio by weight from about 1:20 to about 1:2000. This document also relates to compositions consisting essentially of rolapitant and human serum albumin, wherein the rolapitant and the human serum albumin in the composition have a ratio by weight from about 1:20 to about 1:2000. | 2019-10-10 |
20190307735 | Composition and Methods for Treating Chronic Kidney Disease - This invention relates to the treatment of chronic kidney disease, including diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), nephrotic syndrome, non-diabetic chronic kidney disease, renal fibrosis or acute kidney injury by the administration of an RGD mimetic integrin receptor antagonist, either as a single agent or in combination with other agents. | 2019-10-10 |
20190307736 | FORMULATIONS OF AN LSD1 INHIBITOR - The present application relates to pharmaceutical formulations and dosage forms of a lysine specific demethylase-1 (LSD1) inhibitor, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, including methods of preparation thereof, which are useful in the treatment of LSD1 mediated diseases such as cancer. | 2019-10-10 |
20190307737 | NOVEL PIPERIDINE DERIVATIVES - The invention relates to a compound of formula (I) | 2019-10-10 |
20190307738 | NOVEL DIZOCILPINE DERIVATIVES AS PERIPHERAL NMDA RECEPTOR ANTAGONISTS - The present invention relates to compounds of formula (I) for use as peripheral NMDA receptor antagonists. | 2019-10-10 |
20190307739 | METHODS AND COMPOSITIONS FOR TREATMENT OF DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION - The present disclosure provides a method of treating a central nervous system disorder in a patient in need thereof. The method comprises orally administering between 75 mg and 300 mg xanomeline salt and between 20 mg and 200 mg trospium chloride to the patient during a 24-hour period, the central nervous system disorder being selected from schizophrenia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Lewy Body dementia, wherein use of the trospium chloride alleviates a side effect associated with use of the xanomeline salt. | 2019-10-10 |
20190307740 | COMPOSITIONS AND METHODS FOR TREATMENT RELATED TO FALL AND FALL FREQUENCY IN NEURODEGENERATIVE DISEASES - The present disclosure provides methods and compositions for treating fall-related symptoms in patients with neurodegenerative diseases such as Parkinson's disease or Parkinson-related diseases. In some embodiments, the disclosure utilizes nicotine or a salt thereof in combination of dopaminergic agent treatments for reducing fall-related symptoms such as reducing frequency of fall, reducing injuries related to fall, reducing severity of injuries related to fall, freezing of gait, improving posture stability, improving locomotion ability, improving balance and gait. In some embodiments, the methods predict fall frequency and tendency of recurrent falls in patients with Parkinson's disease, in particular, patients with typical Parkinson's disease. | 2019-10-10 |
20190307741 | VINFLUNINE AND PD1 AND/OR PDL1 INHIBITOR AS PHARMACEUTICAL COMBINATION - The present invention relates to a pharmaceutical combination comprising: (a) vinflunine or a pharmaceutically acceptable salt thereof, and (b) at least one PD1-inhibitor and/or at least one PD-L1-inhibitor or pharmaceutically acceptable salt thereof. Such a pharmaceutical combination is useful as a drug, notably in the treatment of a proliferative disease, such as cancer. | 2019-10-10 |
20190307742 | METHODS FOR TREATING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN - The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient. | 2019-10-10 |
20190307744 | PHARMACEUTICAL COMPOSITIONS COMPRISING CLOFAZIMINE ANALOG COMPOUND B746 OR CLOFAZIMINE ANALOG COMPOUND B826 - Methods for treating a subject infected with | 2019-10-10 |
20190307745 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF - The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further relates to, but is not limited to, methods for suppressing tumor cell growth, ameliorating the pathogenesis of systemic lupus erythematosus, and the treatment of various other disorders, including Noonan syndrome, diabetes, neutropenia, neuroblastoma, melanoma, juvenile leukemia, juvenile myelomonocytic leukemia, chronic myelomonocytic leukemia, acute myeloid leukemia, and other cancers associated with SHP2 deregulation with the compounds and compositions of the invention, alone or in combination with other treatments. Other cancers associated with SHP2 deregulation include HER2-positive breast cancer, triple-negative breast cancer, ductal carcinoma of the breast, invasive ductal carcinoma of the breast, non-small cell lung cancer, esophageal cancer, gastric cancer, squamous-cell carcinoma of the head and neck (SCCHN), and colon cancer. | 2019-10-10 |
20190307746 | METHODS OF TREATING COCHLEAR SYNAPTOPATHY - The present application describes the use of gamma secretase inhibitors and gamma secretase modulators for the treatment of cochlear synaptopathy. | 2019-10-10 |
20190307747 | ALLOSTERIC CORTICOTROPIN-RELEASING FACTOR RECEPTOR 1 (CRFR1) ANTAGONISTS THAT DECREASE P-TAU AND IMPROVE COGNITION - In various embodiments novel allosteric antagonists of the CRFR1 receptor are provided. It discovered that allosteric CRFR1 receptor antagonists are effective to modulate p-Tau levels in Alzheimer's disease (AD) models. | 2019-10-10 |
20190307748 | TREATMENT OR PREVENTION OF AUTISM DISORDERS USING MENTHOL, LINALOOL AND/OR ICILIN - Compositions for treatment or prevention of autism disorders are provided, and the compositions contain a therapeutically effective amount of a compound selected from the group consisting of Menthol, Linalool, Icilin and combinations thereof. Methods for treatment or prevention of autism disorders are also provided, and the methods include administering such compositions. | 2019-10-10 |
20190307749 | Mitochondria-Division Inhibitor 1 Protects Against Amyloid-B Induced Mitochondrial Fragmentation and Synaptic Damage in Alzheimer's Disease - The present invention includes a method for preventing or treating a disease or condition with excessive fragmentation of mitochondria or mitochondrial dysfunction comprising, consisting essentially of, or consisting of: identifying a subject suspected of needing treatment for excessive fragmentation of mitochondria or mitochondrial dysfunction; and administering to the subject with an amount of a mitochondrial division inhibitor 1 sufficient to prevent or treat the excessive fragmentation of mitochondria or mitochondrial dysfunction. | 2019-10-10 |
20190307750 | TARGETING CHROMATIN REGULATORS INHIBITS LEUKEMOGENIC GENE EXPRESSION IN NPM1 MUTANT LEUKEMIA - Disclosed are methods for inhibiting proliferation of or inducing apoptosis in certain leukemia cells or both. The methods comprise contacting a leukemia cell exhibiting an NPM1 mutation with a pharmacologic inhibitor of interaction between MLL and menin. More broadly, disclosed are methods for treating a susceptible leukemia using pharmacologic inhibition of Menin-MLL interaction. Also disclosed are methods for treating such leukemias using inhibition of Menin-MLL interaction in combination with DOT1L inhibition. | 2019-10-10 |
20190307751 | G PROTEIN-COUPLED RECEPTOR (GPCR) MODULATION BY IMIPRIDONES - Imipridones has been found to selectively modulate Class A G protein-coupled receptors (GPCRs), such as the D2-like subfamily of dopamine receptors, and to be useful for the treatment of conditions and disorders in need of such modulation, such as cancers, psychiatric disorders, and bacterial infections. In addition, methods of identifying whether a subject having these condition, is likely to be responsive to a treatment regimen, such as administration of an imipridone, are provided. Furthermore, methods of assessing the effectiveness of a treatment regimen, such as administration of an imipridone, monitoring, or providing a prognosis for a subject with these condition are also provided. | 2019-10-10 |
20190307752 | Inhibitors of the Unconventional Secretion of Fibroblast Growth Factor 2 (FGF2) by Tumor Cells and Uses Thereof - The present invention relates to compounds that have the capability of inhibiting the secretion of fibroblast growth factor 2 (FGF2) by tumor cells, as well as uses of said compound in medicine, in particular in the prevention and/or treatment of cancerous or inflammatory diseases. | 2019-10-10 |
20190307753 | FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS - The invention provides certain fused pyrazine compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, R | 2019-10-10 |
20190307754 | PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES - The present invention relates to PDE9 inhibitors, their synthesis, and their use for treatment of benign prostate hyperplasia, beta thalassemia, and sickle cell disease. | 2019-10-10 |
20190307755 | POLYGLUTAMATED ANTIFOLATES AND USES THEREOF - The disclosure relates generally to polyglutamated antifolates, formulations containing liposomes filled with the polyglutamated antifolates, methods of making the polyglutamated antifolates and liposome containing formulations, and methods of using the polyglutamated antifolates and liposome containing formulations to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis). | 2019-10-10 |